Chief Operating Officer
Andrew Aromando joined Ambrx as Chief Operating Officer in April 2023. Mr. Aromando is an accomplished biopharmaceutical executive with over 30 years of clinical and commercial industry experience. He has a proven track record of demonstrated expertise in oncology product development, business development, corporate strategy and operational excellence. Prior to Ambrx, he served in C-level positions for 15 years at multiple oncology-focused biotech and specialty pharmaceutical companies. He also served in senior leadership roles at IQVIA, Syneos Health and WCG, focused on development of clinical and commercial solutions for early and late-stage clinical product candidates, new products and mature brands across therapeutic areas. He began his career in field sales at Novartis.
Mr. Aromando holds a B.A. from The College of New Jersey and a M.A. from Rutgers University.